Liquid biopsy testing built around circulating tumor cells to guide treatment and monitor disease.
Consented intake · your records travel with you · nothing moves without your sign-off
RGCC analyzes blood and other bodily fluids for biomarkers, with a focus on circulating tumor cells. The testing is designed to gather distinctive markers that can guide treatment and monitor disease progression, including minimum residual disease monitoring and early detection. It gives patients another window into how their cancer is behaving over time.
Prefer the source? RGCC (circulating tumor cells)'s own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how RGCC (circulating tumor cells) handles billing.
We don't have confirmed insurance details for RGCC (circulating tumor cells) yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in RGCC's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Finds clinical trials you actually qualify for — matched to your tumor's biomarkers and treatment history, not a generic keyword search.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.